Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
News|Podcasts|August 17, 2026
ACT Brief: Data Standardization Bottleneck in Real-Time Monitoring, US Biotech FIH Trial Regulatory Frustration, and FDA Approval of Zenbexus for Multiple Myeloma
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine the standardization gap that sits between raw data collection and real-time analysis, why regulatory unpredictability is pushing US biotechs to run early trials overseas, and FDA accelerated approval of a new immunomodulatory therapy.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In a
new Q&A , Raviv Pryluk, PhD, CEO and co-founder of PhaseV, discussed the "dead time" delay between when data is collected and when it becomes analysis-ready for real-time monitoring. AI automation of data mapping and standardization to industry standards is beginning to compress this bottleneck, making continuous review operationally feasible at scale for sponsors beyond large pharma. - A
new survey of 37 US biotech executives found that 72% prefer domestic first-in-human trials but are hesitant due to regulatory unpredictability and clinical holds, causing 73% to cite delays and costs as reasons for overseas migration. When FDA review criteria are predictable, the US ranks first for 76% of companies, but historical practices have pushed development toward Australia and other jurisdictions. - The
FDA granted accelerated approval to Zenbexus for use with daratumumab and dexamethasone in multiple myeloma patients with at least one prior treatment, based on the Phase III trial showing 41% of patients achieved the deepest response measure compared to 21% with standard therapy. Zenbexus represents the first approved option in a new class of therapies designed to activate protein degradation in cancer cells.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine proportionate analysis frequency in RBQM, how to build trust into real-world evidence foundations for cancer trials, and how rare disease developers monetize regulatory success.
In today's ACT Brief, we examine how AI surfaces design flaws before enrollment, why site training readiness depends on learning science, and the priorities defining next-generation weight-loss therapies.
In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
Trending on Applied Clinical Trials Online
1
Real-Time Data, Right-Time Decisions: Rethinking Analysis Frequency in RBQM
2
What It Takes to Harmonize AI Across Fragmented Oncology Health Systems
3
Using AI to Design Better Trials Before the First Patient Enrolls: Q&A with Claire Riches, Citeline
4
FDA Releases Transparency Roadmap Outlining Disclosure Priorities Across Drug Development and Regulatory Review
5